KURA
Kura Oncology, Inc.
$9.88
-0.10
(-1.00%)
Mkt Cap
878.93M
Volume
1,155,038
52W Range
7.358-13.9
Sector
Healthcare
Beta
0.38
EPS (TTM)
-3.37 USD
P/E Ratio
-3.27
Revenue (TTM)
77.22M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.48M | 53.88M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (278.67M) | (173.98M) | (152.63M) | (135.84M) | (130.47M) | (89.62M) | (63.14M) | (60.45M) | (35.43M) | (27.56M) | (22.62M) | (11.01M) |
| EPS | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 | -1.72 | -1.52 | -1.47 | -2.28 | -2.69 |
| Free Cash Flow | (70.70M) | 133.84M | (124.99M) | (110.69M) | (105.70M) | (72.00M) | (54.76M) | (48.66M) | (28.44M) | (25.35M) | (17.99M) | (2,631) |
| FCF / Share | -0.81 | 1.55 | -1.71 | -1.65 | -1.59 | -1.36 | -1.31 | -1.38 | -1.22 | -1.36 | -1.81 | -0.00 |
| Operating CF | (64.06M) | 134.32M | (124.82M) | (110.06M) | (104.55M) | (69.83M) | (54.76M) | (48.66M) | (28.44M) | (25.35M) | (17.93M) | (2,547) |
| Total Assets | 738.36M | 760.16M | 448.94M | 456.31M | 534.05M | 647.21M | 241.97M | 182.38M | 95.85M | 69.82M | 87.26M | 1.38M |
| Total Debt | 20.46M | 16.59M | 17.20M | 14.02M | 6.88M | 14.98M | 7.75M | 7.50M | 7.10M | 7.32M | 0 | 2.53M |
| Cash & Equiv | 149.10M | 224.46M | 37.32M | 51.80M | 90.67M | 325.49M | 26.14M | 16.12M | 11.43M | 9.72M | 15.44M | 1.12M |
| Book Value | 174.13M | 413.64M | 397.27M | 420.28M | 506.61M | 610.90M | 218.78M | 160.99M | 79.86M | 56.88M | 82.10M | (3.43M) |
| Return on Equity | -1.60 | -0.42 | -0.38 | -0.32 | -0.26 | -0.15 | -0.29 | -0.38 | -0.44 | -0.48 | -0.28 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.87M | 18.27M | 17.34M | 20.75M | 15.29M | 14.11M | 53.88M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (68.33M) | (73.33M) | (81.00M) | (74.12M) | (66.12M) | (57.43M) | (19.22M) | (54.40M) | (50.84M) | (49.52M) | (42.79M) | (38.60M) |
| EPS | -0.77 | -0.83 | -0.92 | -0.85 | -0.75 | -0.66 | -0.22 | -0.63 | -0.59 | -0.59 | -0.55 | -0.50 |
| Free Cash Flow | (63.20M) | (85.98M) | 114.95M | (83.19M) | (30.23M) | (72.22M) | 268.76M | (43.44M) | (42.55M) | (48.93M) | (34.32M) | (29.05M) |
| FCF / Share | -0.71 | -0.97 | 1.31 | -0.95 | -0.35 | -0.83 | 3.08 | -0.50 | -0.49 | -0.58 | -0.44 | -0.38 |
| Operating CF | (62.55M) | (85.85M) | 117.27M | (80.63M) | (28.78M) | (71.93M) | 269.13M | (43.44M) | (42.53M) | (48.84M) | (34.31M) | (29.03M) |
| Total Assets | 587.79M | 652.55M | 738.36M | 649.38M | 682.42M | 743.76M | 760.16M | 478.84M | 515.12M | 553.91M | 448.94M | 473.77M |
| Total Debt | 24.45M | 24.27M | 20.46M | 19.47M | 19.47M | 19.35M | 16.59M | 16.63M | 16.73M | 16.97M | 17.20M | 17.42M |
| Cash & Equiv | 70.24M | 39.08M | 149.10M | 95.29M | 81.95M | 51.27M | 224.46M | 49.48M | 45.18M | 41.51M | 37.32M | 28.74M |
| Book Value | 48.43M | 107.88M | 174.13M | 242.54M | 305.49M | 364.41M | 413.64M | 423.77M | 466.07M | 505.08M | 397.27M | 429.94M |
| Return on Equity | -1.41 | -0.68 | -0.47 | -0.31 | -0.22 | -0.16 | -0.05 | -0.13 | -0.11 | -0.10 | -0.11 | -0.09 |
KURA News
Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
Squarepoint Ops LLC Sells 78,432 Shares of Kura Oncology, Inc. $KURA
Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer